| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | |
|---|---|---|---|---|
| Total operating expenses | 1,146,381 | 799,890 | 15,556,480 | |
| Loss from operations | -1,145,497 | - | - | |
| Interest expense | 1,480,058 | 527,893 | 289,931 | |
| Loss on extinguishment of debt | - | -364,109 | - | |
| Change in fair value of derivative liability | 775,062 | -289,401 | -94,917 | |
| Total other (expense) income, net | -704,996 | -1,181,403 | -384,848 | |
| Net loss | -1,850,493 | -1,981,293 | -15,941,328 | |
| Basic net loss per share of common stock | -0.04 | - | - | |
| Diluted net loss per share of common stock | -0.04 | - | - | |
| Weighted average shares outstanding of common stock, basic | 49,525,970 | - | - | |
| Weighted average shares outstanding of common stock, diluted | 49,525,970 | - | - | |
Aspire Biopharma Holdings, Inc. (ASBP)
Aspire Biopharma Holdings, Inc. (ASBP)